Glutamate ionotropic receptor NMDA type subunit 2A. Every medicine in our data that ChEMBL or the Guide to Pharmacology records as acting on this protein, with the source for each and its current clinical trials on this site.
| Medicine | How it acts | Source | Current trials here |
|---|---|---|---|
| Esketamine CHEMBL395091 |
Glutamate [NMDA] receptor negative allosteric modulator Negative allosteric modulator Small molecule |
ChEMBL only | 50 |
| Ketamine CHEMBL742 |
Glutamate [NMDA] receptor negative allosteric modulator Negative allosteric modulator Small molecule |
✓ Both | 45 |
| Memantine CHEMBL807 |
Glutamate [NMDA] receptor negative allosteric modulator Negative allosteric modulator Small molecule |
ChEMBL only | 7 |
| Dextromethorphan CHEMBL52440 |
Glutamate [NMDA] receptor subunit epsilon 1 antagonist Antagonist Small molecule |
ChEMBL only | 4 |
| Amantadine CHEMBL660 |
Glutamate [NMDA] receptor antagonist Antagonist Small molecule |
✓ Both | 3 |
“Both” means ChEMBL and the Guide to Pharmacology each record this medicine acting on this protein; “only” means one source records it and the other does not (often because it lists fewer secondary targets). The Guide to Pharmacology adds a medicine here only when this protein is its primary target. Medicines without a link have no page on this site yet.
| Disease | Medicines tested | Furthest trial phase |
|---|---|---|
| Bipolar disorder | 4 | Phase 3 |
| Agitation | 3 | Phase 3 |
| Pain | 3 | Phase 3 |
| Anxiety | 3 | Phase 3 |
| Schizophrenia | 3 | Phase 3 |
| Chronic pain | 2 | Phase 3 |
| Cognitive impairment | 2 | Phase 3 |
| Parkinson disease | 2 | Phase 3 |
| Amyotrophic lateral sclerosis | 2 | Phase 3 |
| Autism spectrum disorder | 2 | Phase 3 |
| Depressive disorder | 2 | Phase 3 |
| Major depressive disorder | 2 | Phase 3 |
| Multiple sclerosis symptom measurement | 2 | Phase 3 |
| Alzheimer disease | 1 | Phase 3 |
| COVID-19 | 1 | Phase 3 |
From ChEMBL's drug-disease records, which draw on trial registries. A trial phase is not an approval; approved uses are on each medicine's page from the regulators' own records.
Which medicines act on this protein comes from two independent, expert-curated sources: ChEMBL's mechanism-of-action records (via the Open Targets Platform) and the IUPHAR/BPS Guide to PHARMACOLOGY. Each row says which of them lists it. Data from them is shared here under their share-alike licences (CC BY-SA 3.0 and 4.0).
A job re-reads both sources every 30 days. Medicines are matched to our pages by exact name or a ChEMBL-curated synonym, and to the Guide to Pharmacology by ChEMBL ID or exact name, never by a close spelling. No AI drafting. See our methodology. The Open Targets data on this page was last retrieved on 30 Sep 2026. How every register is built: methodology · fixes we have made: corrections log.
